Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir Mulls Separation As Simeprevir Royalties Decline

Executive Summary

As royalties from hepatitis C therapy simeprevir continue to decline its originator, Swedish biotech Medivir, is considering a separate public listing for its commercial operations that would allow the remaining concern to return to its previous R&D roots.

You may also be interested in...



Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%

Incoming President and CEO John Milligan opened Gilead Sciences Inc.'s first quarter earnings call April 28 talking about sales growth of new HIV drugs and pipeline efforts in non-alcoholic steatohepatitis (NASH), but analysts focused in quickly on overall reductions in hepatitis C sales, including a more than 50% decrease year-over-year in US sales of Harvoni.

Janssen gains FDA nod for HCV protease inhibitor Olysio

The FDA gave Johnson & Johnson subsidiary Janssen Therapeutics approval on 22 November to market Olysio (simeprevir) as a treatment for chronic hepatitis C virus (HCV) as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel